Argenica (ASX: AGN) Jumps 22% as ARG-007 Clears Critical FDA Hurdle

Argenica’s ARG-007 Clears the Way Argenica Therapeutics (ASX: AGN) surged 22% today after confirming that its tenecteplase drug interaction study for ARG 007 met a key FDA requirement needed to…

ByCharlie Youlden

25

Nov 2025

Biotech Stocks News

Is Argenica (ASX:AGN) a Contrarian Buy After 64% Collapse and New Validation Data?

Argenica Therapeutics (ASX: AGN) crashed 70% in September after Phase II trial results disappointed, wiping out over $100 million overnight. This week, the stock surged 20%+ on new data showing…

ByUjjwal Maheshwari

03

Sep 2025

Healthcare Stocks Tech Stocks

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

Argenica Therapeutics Just Faced Its Toughest Test — What Comes Next Argenica Therapeutics Ltd (ASX: AGN) has been thrown into the spotlight after its phase 2 trial results for ARG-007…

ByCharlie Youlden

Argenica (ASX: AGN) Jumps 22% as ARG-007 Clears Critical FDA Hurdle

Is Argenica (ASX:AGN) a Contrarian Buy After 64% Collapse and New Validation Data?

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Argenica (ASX: AGN) Jumps 22% as ARG-007 Clears Critical FDA Hurdle

Is Argenica (ASX:AGN) a Contrarian Buy After 64% Collapse and New Validation Data?

Argenica Therapeutics (ASX: AGN): A 60% Crash or a Second Chance?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here